Association between(combined) health end-points and isocyanate (NCO) exposure for an interquartile range increase (NCO exposure 0.3–2799 μg·m−3·h·month−1) in exposure adjusted for smoking, age, sex and atopy
| Subjects n | PR (95% CI) | |
| BHR20 | 33 | 2.0 (1.1–3.8) |
| FEV1/FVC <70% | 18 | 2.7 (1.1–6.8) |
| eNO ppb ≥ 90th percentile | 22 | 0.8 (0.4–1.6)# |
| Combined parameters | ||
| BHR20 + FEV1/FVC <70% | 10 | 6.1 (1.2–31.7)# |
| BHR20 + eNO ppb ≥90th percentile | 6 | 7.0 (0.7–72.1)¶ |
| BHR20 + asthma-like symptoms | 19 | 2.7 (1.0–6.8) |
| BHR20 + COPD-like symptoms | 15 | 1.5 (0.6–3.9) |
| BHR20 + work-related chest tightness | 3 | 0.9 (0.1–8.3)+ |
| BHR20 + work-related rhinitis | 10 | 2.2 (0.6–8.0)§ |
| BHR20 + work-related conjunctivitis | 7 | 4.3 (0.7–28.0)§ |
PR: prevalence ratio; CI: confidence interval; BHR20: bronchial hyperresponsiveness using a fall in forced expiratory volume in one second (FEV1) of 20% as a cut-off level; FVC: forced vital capacity; eNO: exhaled nitric oxide; COPD: chronic obstructive pulmonary disease. #: adjusted for smoking and atopy; ¶: adjusted for smoking and age; adjustment for atopy resulted in similar PR; +: adjusted for smoking, age and atopy; §: adjusted for smoking, sex and atopy.